Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Osavampator in Treatment-Resistant Depression
NCT03312894Phase 2Withdrawn
- Sponsor
- Millennium Pharmaceuticals
- Start
- Feb 2018
- Primary completion
- Feb 2019
- Modality
- Irreversible Covalent Inhibitors, Orthosteric Ligands
01
Overview
A Phase 2 trial of osavampator in treatment-resistant depression (TRD), sponsored by Millennium Pharmaceuticals. Planned start Feb 2018; status: withdrawn.
02
Drugs
osavampator
03
Conditions
treatment-resistant depression (TRD)
Beyond the preview
Go deeper on NCT03312894.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03312894.